Contact Us
Drug Search Results
More Filters [+]

AV-608

Alternative Names: av-608, av608, av 608
Latest Update: 2008-02-25
Latest Update Note: Clinical Trial Update

Product Description

a neurokinin 1 (NK-1) antagonist for Irritable Bowel Syndrome (IBS) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00316550)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Avera
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AV-608

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Overactive Bladder|Phobia, Social

Phase 1: Irritable Bowel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2005-005868-93

P2

Completed

Overactive Bladder

2007-06-18

AV608-107

P1

Terminated

Irritable Bowel Syndrome

2007-06-01

AV608-106

P2

Terminated

Overactive Bladder

2007-06-01

AV608-105

P2

Completed

Phobia, Social

2006-12-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions